Adaptimmune data confirms ADP-A2M4 delivers clinical benefit
Adaptimmune Therapeutics presented updated data from people with synovial sarcoma treated in the ongoing Phase 1 trial with ADP-A2M4. The oral presentation by Brian Van Tine, MD, PhD of Washington University School of Medicine in St. Louis, took place at the Connective Tissue Oncology Society, or CTOS, annual meeting in Tokyo, Japan. The presentation was an update of the data that Dr. Van Tine presented at ESMO on September 30. Out of the 14 patients with synovial sarcoma who have been treated in the expansion phase of this trial and have post-baseline scans, to date, seven have had clinical responses, representing an overall response rate of 50%. Thirteen patients showed clinical benefit with best overall responses of PR or stable disease - representing a disease control rate of 93%. "This updated data set confirms that ADP-A2M4 continues to deliver clinical benefit, including RECIST responses, to patients with synovial sarcoma. It has also galvanized the support we have received from the sarcoma community, allowing us to rapidly open multiple sites and screen patients for the Phase 2 SPEARHEAD-1 trial," said Elliot Norry, Adaptimmune's acting Chief Medical Officer. "We expect that all sites for SPEARHEAD-1 will be open by the end of the first quarter in 2020, marking another step toward our goal of making this treatment available commercially to people with sarcoma in 2022."